Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study

Journal of Clinical Psychiatry

Volumn 71, Issue 3, 2010, Pages 280-286

  Bobes, Julio ^a,b   Arango, Celso ^b,c   Garcia Garcia, Margarida ^d   Rejas, Javier ^e  

^a UNIVERSITY OF OVIEDO   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Operations Department   (Spain)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ANXIETY; ARTICLE; BLUNTED AFFECT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NEGATIVE SYNDROME; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNEMPLOYMENT;

EID: 77950307734     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04250yel     Document Type: Article

References (30)

1. Lindenmayer JP, Khan A, Iskander A, et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007;68(3):368-379.
2. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? Acta Psychiatr Scand. 2007;115(2):93-100.
3. Milev P, Ho BC, Amdt S, et al. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162(3):495-506.
4. Artaloytia JF, Arango C, Lahti A, et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry. 2006;163(3):488-493.
5. Buchanan RW. Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull. 2007;33(4):1013-1022.
6. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMHMATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31(1):5-19.
7. Peralta V, Cuesta MJ. The deficit syndrome of the psychotic illness: a clinical and nosological study. Eur Arch Psychiatry Clin Neurosci. 2004;254(3):165-171.
8. Möller HG. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs. 2003;17(11):793-823.
9. Stahl SM, Buckley PF. Negative symptoms of schizophrenia: a problem that will not go away. Acta Psychiatr Scand. 2007;115(1):4-11.
10. Carpenter W Jr. Unmet therapeutic needs. Schizophr Bull. 2005;31(4): 793-794.
11. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry. 2008;192(3):161-163.
12. Arango C, Buchanan RW, Kirkpatrick B, et al. The deficit syndrome in schizophrenia: implications for the treatment of negative symptoms. Eur Psychiatry. 2004;19(1):21-26.
13. Bobes J, Arango C, Aranda P, et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90(1-3):162-173.
14. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
15. Peralta Martin V, Cuesta Zorita MJ. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994;22(4):171-177.
16. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538-546.
17. Guy W. Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. Rockville, MD: Nat Inst Ment Health; 1976.
18. van Os J, Walsh E, van Horn E, et al. Changes in negative symptoms and the risk of tardive dyskinesia: a longitudinal study. UK700 Group. Acta Psychiatr Scand. 2000;101(4):300-306.
19. Bejerholm U, Eklund M. Occupational engagement in persons with schizophrenia: relationships to self-related variables, psychopathology, and quality of life. Am J Occup Ther. 2007;61(1):21-32.
20. Kirkpatrick B, Buchanan RW, Ross DE, et al. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001; 58(2):165-171.
21. Pini S, de Queiroz V, Dell'Osso L, et al. Cross-sectional similarities and differences between schizophrenia, schizoaffective disorder and mania or mixed mania with mood-incongruent psychotic features. Eur Psychiatry. 2004;19(1):8-14.
22. Azorin JM, Kaladjian A, Fakra E. Current issues on schizoaffective disorder. Encephale. 2005;31(3):359-365.
23. Kirkpatrick B, Fenton WS, Carpenter WT, et al. The NIMHMATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214-219.
24. Kirkpatrick B, Buchanan RW, McKenny PD, et al. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30(2):119-123.
25. Kirkpatrick B, Buchanan RW, Breier A, et al. Case identification and stability of the deficit syndrome of schizophrenia. Psychiatry Res. 1993;47(1):47-56.
26. Goetz RR, Corcoran C, Yale S, et al. Validity of a 'proxy' for the deficit syndrome derived from the Positive and Negative Syndrome Scale (PANSS). Schizophr Res. 2007;93(1-3):169-177.
27. Carpenter WT Jr, Arango C, Buchanan RW, et al. Deficit psychopathology and a paradigm shift in schizophrenia research. Biol Psychiatry. 1999;46(3):352-360.
28. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2004;7(suppl 1):S15-S20.
29. Carpenter WT Jr. Serotonin-dopamine antagonists and treatment of negative symptoms. J Clin Psychopharmacol. 1995;15(suppl 1):30S-35S.
30. Lecrubier Y, Quintin P, Bouhassira M, et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand. 2006;114(5):319-327.